Cancer News and Research

Latest Cancer News and Research

NIH selects Salk scientist for EUREKA grant

The National Institutes of Health has selected Axel Nimmerjahn for a highly competitive EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant. Dr. Nimmerjahn is an Assistant Professor in the Waitt Advanced Biophotonics Center and holds the Richard Allan Barry Developmental Chair.

13 Oct 2013

Study evaluates possibility of individualisation of castration-resistant prostate cancer management

A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.

12 Oct 2013

WHO: Iron deficiency causes loss of 48,225 disability-adjusted life-years worldwide

Data supporting the need for better recognition of iron deficiency will be presented this week at the United European Gastroenterology Week Congress in Berlin. Iron deficiency is frequently under-diagnosed, resulting in increased hospitalisation, reduced quality of life and higher death rates in patients with comorbid conditions. The WHO has estimated that iron deficiency causes the loss of 48,225 disability-adjusted life-years worldwide, more than is seen with lung cancer.

12 Oct 2013

Resveratrol can make tumor cells more susceptible to radiation treatment

A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, follows a previous MU study that found similar results in the treatment of prostate cancer.

12 Oct 2013

Research findings may lead to new ways to combat cancer

The way cells divide to form new cells - to support growth, to repair damaged tissues, or simply to maintain our healthy adult functioning - is controlled in previously unsuspected ways UC San Francisco researchers have discovered.

12 Oct 2013

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

Drug abuse and alcohol are some of the most frequent causes of liver damage, particularly in developed countries. Such kind of liver damage can cause irreversible liver failure and even cancer. Researchers from the Spanish National Cancer Research Centre have discovered an important new protective role of the Fra-1 protein, which neutralizes the damage caused by agents, such as the analgesic drug acetaminophen (Paracetamol).

12 Oct 2013

UTHealth professor receives Oswald Avery Award for Early Achievement from IDSA

Cesar Arias, M.D., Ph.D., associate professor in the Division of Infectious Diseases at The University of Texas Health Science Center at Houston Medical School, was bestowed the Oswald Avery Award for Early Achievement from the Infectious Diseases Society of America.

12 Oct 2013

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Development of a vaccine against Epstein-Barr virus has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.

12 Oct 2013

Island Doctors to host community diabetes awareness campaigns across NE Florida

On October 12th and 13th, Island Doctors will participate, sponsor, and co-host three events in Putnam and St. Johns County, Florida. The events are part of Island Doctors continued commitment to community diabetes awareness campaigns across NE Florida.

12 Oct 2013

Gov't. shutdown creates difficult issues at NIH

The National Institutes of Health is trying to cope with the effects of the government shutdown on patients and medical research.

12 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

First Edition: October 11, 2013

Today's headlines include news about what experts are diagnosing as the trouble spots in the federal online health insurance exchange and how to fix them.

11 Oct 2013

ImmunoGen signs new license agreement with Novartis

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.

11 Oct 2013

Experts suggest interventions to help reduce delays in diagnosis of cancer in primary care

Continuity of care so that all patients see the same GP with whom they build up a relationship over time could help reduce delays in the diagnosis of cancer in primary care. In an essay published by the Journal of the Royal Society of Medicine, a team of primary care experts write that this, together with longer consultations and better distribution of information to GPs about referral pathways or new services could have a wide reaching impact on the early diagnosis of cancer and survival.

11 Oct 2013

Report provides new estimates of breast cancer rates among active component service women

Crude incidence rates of breast cancer among U.S. female active component service members have fluctuated slightly over the past 12 years, but have remained relatively stable, according to a new study.

11 Oct 2013

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

11 Oct 2013

Cancer News and Research

Latest Cancer News and Research

NIH selects Salk scientist for EUREKA grant

Study evaluates possibility of individualisation of castration-resistant prostate cancer management

WHO: Iron deficiency causes loss of 48,225 disability-adjusted life-years worldwide

Resveratrol can make tumor cells more susceptible to radiation treatment

Research findings may lead to new ways to combat cancer

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

UTHealth professor receives Oswald Avery Award for Early Achievement from IDSA

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Island Doctors to host community diabetes awareness campaigns across NE Florida

Gov't. shutdown creates difficult issues at NIH

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

First Edition: October 11, 2013

ImmunoGen signs new license agreement with Novartis

Experts suggest interventions to help reduce delays in diagnosis of cancer in primary care

Report provides new estimates of breast cancer rates among active component service women

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in